Evidence map›Paper›PMID 37660157›Full record

ArticleBone marrow transplantation2023

The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT.

Arnon Nagler, Myriam Labopin, Nicolaus Kröger, Thomas Schroeder, Tobias Gedde-Dahl, Matthias Eder, Georg-Nikolaus Franke, Igor Wolfgang Blau, Urpu Salmenniemi, Gerard Socie and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 5 countries.

Arnon NaglerDivision of Hematology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. arnon.nagler@sheba.health.gov.il.ORCID http://orcid.org/0000-0002-0763-1265
Myriam LabopinEBMT Paris study office; Department of Haematology, Saint Antoine Hospital, Sorbonne University, INSERM UMR 938, Paris, France.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Medical Center, Hamburg, Germany.ORCID http://orcid.org/0000-0001-5103-9966
Thomas SchroederUniversity Hospital, Department of Bone Marrow Transplantation, Essen, Germany.
Tobias Gedde-DahlOslo University Hospital, Rikshospitalet Clinic for Cancer Medicine, Hematology Department, Section for Stem Cell Transplantation, Oslo, Norway.
Matthias EderHannover Medical School, Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany.
Georg-Nikolaus FrankeMedical Clinic and Policinic 1, Hematology and Cellular Therapy University hospital Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0001-8239-002X
Igor Wolfgang BlauCharité, University medicine Berlin, Department of Hematology, BMT Unit, Berlin, Germany.
Urpu SalmenniemiHUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.
Gerard SocieHopital St. Louis, Department of Hematology-BMT, Paris, France.ORCID http://orcid.org/0000-0002-2114-7533
Johannes ScheteligUniversitaetsklinikum Dresden Medizinische Klinik und Poliklinik I, Dresden, Germany.ORCID http://orcid.org/0000-0002-2780-2981
Matthias StelljesUniversity of Muenster Department of Hematol. /Oncol., Muenster, Germany.
Fabio CiceriHematology & Bone Marrow Transplant, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID http://orcid.org/0000-0003-0873-0123
Mohamad MohtyEBMT Paris study office; Department of Haematology, Saint Antoine Hospital, Sorbonne University, INSERM UMR 938, Paris, France.ORCID http://orcid.org/0000-0002-7264-808X
Inserm · FRCharité - Universitätsmedizin Berlin · DEEssen University Hospital · DEHôpital Saint-Louis · FRMedizinische Hochschule Hannover · DEOslo University Hospital · NOSheba Medical Center · ILUniversität Hamburg · DEUniversity Hospital Leipzig · DEUniversity of Münster · DEVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We compared outcomes, of 1609 patients with secondary acute myeloid leukemia (sAML) undergoing allogeneic transplantation (HSCT) in first complete remission (CR1) from matched unrelated donors (MUD) from 2010 to 2021, receiving or not receiving anti-thymocyte globulin (ATG) (ATG-1308, no ATG-301). Median age was 60.9 (range, 18.5-77.8) and 61.1 (range, 21.8-75.7) years, (p = 0.3). Graft versus host disease (GVHD) prophylaxis was cyclosporin-A with methotrexate (41%) or mycophenolate mofetil (38.2%), without significant differences between groups. Day 28, engraftment (ANC > 0.5 × 10

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAntilymphocyte SerumChronic DiseaseHumansMiddle AgedRecurrenceRetrospective StudiesTransplantation ConditioningUnrelated DonorsAntilymphocyte Serum

Identifiers

PMID37660157
OpenAlexW4386393161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.